目的：观察贝伐珠单抗治疗恶性肿瘤的相关不良反应及处理方法。方法：13例恶性肿瘤患者,均接受含贝伐珠单抗药物治疗,及时记录并处理与之相关的不良反应。结果：13例患者治疗过程中出现：2例高血压(CTC 2级),4例少量出血(CTC 1级),1例皮疹(CTC 1级),4例蛋白尿(CTC 1级),不良反应轻微,发生率低,及时处理相关不良反应非常必要,未见严重不良事件。结论：贝伐珠单抗是抗肿瘤血管生成的靶向治疗新药,安全性好,不良反应少。%Objective:To observe related adverse events and management principles to bevacizumab in the treatment of malignant tumors. Methods:13 cases of malignant tumor patients, treated with bevacizumab therapy, timely recorded and treated associated with adverse reactions.Results: 0f the 13 patients during the course of treatment, those with 2 cases of hypertension (CTC 2), 4cases of bleeding (CTC 1), 1 cases of skin rash (CTC 1), 4 cases of urinary protein (CTC 1). The adverse reactions were slight, occurence rate wrere low, however timely processing of related adverse reaction was very necessary, there were no serious adverse events. Conclusions:Bevacizumab was anti angiogenesis in tumor targeted therapy drugs with good safety as well as less adverse reaction.
展开▼
